Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J O'Callaghan

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2013
PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17Christos S Karapetis, Derek Jonker, Manijeh Daneshmand, et al.
The Lancet. Oncology|September 8, 2024
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 studyLaura A Dawson, Jolie Ringash, Alysa Fairchild, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II TrialNick Pavlakis, Katrin M Sjoquist, Andrew J Martin, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 20, 2016
Effects of a Structured Exercise Program on Physical Activity and Fitness in Colon Cancer Survivors: One Year Feasibility Results from the CHALLENGE TrialKerry S Courneya, Janette L Vardy, Christopher J O'Callaghan, et al.
BMC Cancer|February 23, 2023
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, et al.
JCO Clinical Cancer Informatics|April 29, 2026
Deep Learning of Histopathology Predicts Outcomes After Surgery for Pancreatic CancerAvelyn Wong, Taib A Bourega, Rémy Nicolle, et al.
JCO Precision Oncology|October 5, 2020
Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 TrialElisa Fontana, Gift Nyamundanda, David Cunningham, et al.
The New England Journal of Medicine|March 16, 2017
Short-Course Radiation plus Temozolomide in Elderly Patients with GlioblastomaJames R Perry, Normand Laperriere, Christopher J O'Callaghan, et al.
The New England Journal of Medicine|June 1, 2025
Structured Exercise after Adjuvant Chemotherapy for Colon CancerKerry S Courneya, Janette L Vardy, Christopher J O'Callaghan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2026
Structured exercise program following adjuvant chemotherapy for colon cancer: A cost-utility analysis of the CHALLENGE trialKelvin Kw Chan, Ryan Wk Chu, Matthew C Cheung, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2013
PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17Christos S Karapetis, Derek Jonker, Manijeh Daneshmand, et al.
The Lancet. Oncology|September 8, 2024
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 studyLaura A Dawson, Jolie Ringash, Alysa Fairchild, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II TrialNick Pavlakis, Katrin M Sjoquist, Andrew J Martin, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 20, 2016
Effects of a Structured Exercise Program on Physical Activity and Fitness in Colon Cancer Survivors: One Year Feasibility Results from the CHALLENGE TrialKerry S Courneya, Janette L Vardy, Christopher J O'Callaghan, et al.
BMC Cancer|February 23, 2023
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, et al.
JCO Clinical Cancer Informatics|April 29, 2026
Deep Learning of Histopathology Predicts Outcomes After Surgery for Pancreatic CancerAvelyn Wong, Taib A Bourega, Rémy Nicolle, et al.
JCO Precision Oncology|October 5, 2020
Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 TrialElisa Fontana, Gift Nyamundanda, David Cunningham, et al.
The New England Journal of Medicine|March 16, 2017
Short-Course Radiation plus Temozolomide in Elderly Patients with GlioblastomaJames R Perry, Normand Laperriere, Christopher J O'Callaghan, et al.
The New England Journal of Medicine|June 1, 2025
Structured Exercise after Adjuvant Chemotherapy for Colon CancerKerry S Courneya, Janette L Vardy, Christopher J O'Callaghan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2026
Structured exercise program following adjuvant chemotherapy for colon cancer: A cost-utility analysis of the CHALLENGE trialKelvin Kw Chan, Ryan Wk Chu, Matthew C Cheung, et al.
Pageof 5